Business Description
Capricor Therapeutics Inc
NAICS : 325414
SIC : 2834
ISIN : US14070B1017
Total Employee Number:
231Description
Capricor Therapeutics Inc is a clinical-stage biotechnology company based in the United States that develops cell and exosome-based therapeutics for rare diseases. Its lead candidate, deramiocel (CAP-1002), is an allogeneic cardiac-derived cell therapy in late-stage clinical development for Duchenne muscular dystrophy, a rare genetic disorder causing progressive muscle degeneration. The company also operates its StealthX exosome platform, which is used in preclinical research for vaccine development and the delivery of oligonucleotides, proteins, and small molecules. Capricor's efforts target diseases with high unmet medical need, particularly neuromuscular and cardiac conditions. As a clinical-stage company, it does not yet generate product revenue; funding comes primarily from equity financings, research grants, and partnership arrangements, including a collaboration with Nippon Shinyaku for the development and commercialization of deramiocel in Japan.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.61 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.37 | |||||
Debt-to-EBITDA | -0.72 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -21.9 | |||||
3-Year EPS without NRI Growth Rate | -25.8 | |||||
3-Year Book Growth Rate | 125.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 54 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 68.79 | |||||
9-Day RSI | 59.39 | |||||
14-Day RSI | 52.49 | |||||
3-1 Month Momentum % | -72.61 | |||||
6-1 Month Momentum % | -74.68 | |||||
12-1 Month Momentum % | 29.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.35 | |||||
Quick Ratio | 7.35 | |||||
Cash Ratio | 7.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -31.5 | |||||
Shareholder Yield % | -6.65 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -63.47 | |||||
ROA % | -49.36 | |||||
ROIC % | -210.69 | |||||
3-Year ROIIC % | -304.46 | |||||
ROC (Joel Greenblatt) % | -277.56 | |||||
ROCE % | -56 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 243.43 | |||||
PB Ratio | 2.26 | |||||
Price-to-Tangible-Book | 2.25 | |||||
EV-to-EBIT | -2.99 | |||||
EV-to-Forward-EBIT | -3.26 | |||||
EV-to-EBITDA | -3.03 | |||||
EV-to-Forward-EBITDA | -2.05 | |||||
EV-to-Forward-Revenue | 57.72 | |||||
EV-to-FCF | -2.62 | |||||
Price-to-GF-Value | 2 | |||||
| Price-to-Net-Current-Asset-Value | 4.63 | |||||
| Price-to-Net-Cash | 4.8 | |||||
Earnings Yield (Greenblatt) % | -33.44 | |||||
FCF Yield % | -24.3 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Capricor Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -2.1 | ||
| Beta | 0.3504 | ||
| 3-Year Sharpe Ratio | 0.69 | ||
| 3-Year Sortino Ratio | 3.01 | ||
| Volatility % | 499.08 | ||
| 14-Day RSI | 52.49 | ||
| 14-Day ATR (€) | 0.560187 | ||
| 20-Day SMA (€) | 7.6462 | ||
| 12-1 Month Momentum % | 29.86 | ||
| 52-Week Range (€) | 2.576 - 30.1 | ||
| Shares Outstanding (Mil) | 58.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Capricor Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Capricor Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-03-17 | In 176 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-03-12 16:30 | In 172 days | ||
| Fourth quarter earnings results for 2026 | 2027-03-12 | In 171 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-10 16:30 | In 50 days | ||
| Third quarter earnings results for 2026 | 2026-11-10 | In 49 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-13 16:30 | 3.41 (+0.15%) | ||
| Second quarter earnings results for 2026 | 2026-08-13 | 3.41 (+0.15%) | ||
| Guidance call for 2026 | 2026-06-27 | 25.89 (+0.00%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-10 10:00 | 22.12 (+0.05%) | ||
| General meeting for 2026 | 2026-06-04 10:00 | 23.17 (+1.05%) |
Show
Entries
Capricor Therapeutics Inc Frequently Asked Questions
What is Capricor Therapeutics Inc(FRA:4LN2)'s stock price today?
The current price of FRA:4LN2 is €7.81. The 52 week high of FRA:4LN2 is €30.10 and 52 week low is €2.58.
When is next earnings date of Capricor Therapeutics Inc(FRA:4LN2)?
The next earnings date of Capricor Therapeutics Inc(FRA:4LN2) is 2026-11-10 Est..
Does Capricor Therapeutics Inc(FRA:4LN2) pay dividends? If so, how much?
Capricor Therapeutics Inc(FRA:4LN2) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers